Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;3(2):229-34.
doi: 10.2147/vhrm.2007.3.2.229.

Epidemiology, classification, and modifiable risk factors of peripheral arterial disease

Affiliations
Review

Epidemiology, classification, and modifiable risk factors of peripheral arterial disease

Nicolas W Shammas. Vasc Health Risk Manag. 2007.

Abstract

Peripheral arterial disease (PAD) is part of a global vascular problem of diffuse atherosclerosis. PAD patients die mostly of cardiac and cerebrovascular-related events and much less frequently due to obstructive disease of the lower extremities. Aggressive risk factors modification is needed to reduce cardiac mortality in PAD patients. These include smoking cessation, reduction of blood pressure to current guidelines, aggressive low density lipoprotein lowering, losing weight, controlling diabetes and the use of oral antiplatelet drugs such as aspirin or clopidogrel. In addition to quitting smoking and exercise, cilostazol and statins have been shown to reduce claudication in patients with PAD. Patients with critical rest limb ischemia or severe progressive claudication need to be treated with revascularization to minimize the chance of limb loss, reduce symptoms, and improve quality of life.

PubMed Disclaimer

References

    1. Anderson PL, Gelijns A, Moskowitz A, et al. Understanding trends in inpatient surgical volume: vascular intervention, 1980–2000. J Vasc Surg. 2004;9:1200–8. - PubMed
    1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86. - PMC - PubMed
    1. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711–2. - PubMed
    1. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. METS-GREECE Collaborative Group Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin. 2004;20:1691–701. - PubMed
    1. Bhatt D. REACH (Reduction of Atherothrombosis for Continued Health) registry. American College of Cardiology Annual Scientific Session; March 8, 2005.2005.

Publication types